Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Comparison of Gan & Lee Insulin Lispro Injection and EU-authorized Humalog in Adult Type 1 Diabetes Mellitus
2017-001657-13Phase 3Terminated
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin lispro in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Treatment-induced anti-insulin antibodies (AIAs) up to Week 26. Started Jul 2019; status: terminated.
02
Drugs
insulin lispro
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2017-001657-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001657-13.